- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Identification of Agitation in Patients with Dementia due to Alzheimer’s Disease: Perspectives from the Primary Care Provider

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Identification of Agitation in Patients with Dementia due to Alzheimer’s Disease: Perspectives from the Primary Care Provider
Join us for a discussion with Dr. C. Brendan Montano, as he shares his perspective from the primary care setting on identifying and responding to agitation associated with dementia due to Alzheimer’s disease. The discussion will explore the prevalence and burden of agitation in Alzheimer’s dementia, recognition of agitation symptoms, as well as the use of the AASC™, a brief screening tool based on the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders. This tool is designed to assist caregivers in recognizing AAD and starting the conversation with their medical provider.

C. Brendan Montano, MD, PC
Director and Principal Investigator for Connecticut Clinical Research in Cromwell, Connecticut
More

Amaka Onyereri, PharmD, BCPS
Medical Science Liaison
More

Lindsay Teliska, PhD
Medical Science Liaison, Otsuka Pharmaceutical Development & Commercialization, Inc.
Dr. C. Brendan Montano is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.
Amaka Onyereri is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Lindsay Teliska is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
November 2024 US.CORP.X.24.00325